Equity Genie

$CUE is one small-cap biotech I’m watching after a major reset. The company recently brought in a new CEO, raised ~$30M through a private placement, earned a $7.5M milestone from Boehringer Ingelheim, and added a Phase 2 anti-IgE allergy asset. The company recently: • Brought in a new CEO • Raised ~$30M through a private placement • Earned a $7.5M milestone from Boehringer Ingelheim • Added a Phase 2 anti-IgE allergy asset • Set up a potential Phase 2 data catalyst in 2H 2026 Watching into 2H 2026. Not financial advice. The story now is whether fresh capital, new leadership, and partnered platform validation can translate into meaningful clinical progress. Communicated Disclaimer stockresearchtoday.com/cue/ $BYND $OPEN

@EliteGainzTrade Excited for the future on this one

🚨 $CUE Gaining Attention With Big 2026 Catalysts. The Cancer immunotherapy market is a $150B–$200B+ projected global market this decade. CUE continues advancing its Immuno-STAT platform across cancer and autoimmune diseases. ➡️ Presenting at the Jefferies Global Healthcare Conference on June 3rd ➡️ Expanded pipeline with Ascendant-221 targeting allergic diseases ➡️ Secured $30M private placement to fuel growth ➡️ Received $7.5M milestone payment from Boehringer Ingelheim With exposure to major oncology and immunology markets, CUE is entering a new phase of growth in biotech. A name to keep on your radar into 2027! Communicated-Disclaimer- stockresearchtoday.com/cue/

@TheShortSqueezy Excited for what the future brings on this

🚨 $CUE Entering a New Growth Phase With Major 2026 Catalysts Cue Biopharma is developing targeted immune therapies designed to selectively activate the body’s immune system for cancer and autoimmune diseases using its proprietary Immuno-STAT platform. Cue Biopharma continues stacking catalysts in 2026: 🔹 Presenting at the Jefferies Global Healthcare Conference on June 3rd, giving CUE major exposure to institutional healthcare investors. 🔹 Expanded pipeline with Ascendant-221, a clinical stage anti-IgE antibody targeting allergic diseases and expanding CUE into large immunology markets. 🔹 Company also secured a $30M private placement to strengthen the balance sheet and support pipeline expansion. 🔹 Received a $7.5M milestone payment from Boehringer Ingelheim, further validating the company’s immune-modulation platform. With oncology and allergy/immunology markets representing multi billion dollar opportunities globally, CUE is positioning itself in some of the largest and fastest-growing areas in biotech. Communicated Disclaimer: stockresearchtoday.com/cue/ Sector peers: $MRNA $BNTX $ADAP $NKTX $IMTX $SANA $CRSP $BEAM $XCUR $HOOK $INMB $ABCL $RVPH $XBI

@JTE_ThetaCo Love that chart

$CUE IS BUILDING THE FUTURE OF IMMUNE THERAPY🧬 Cue is a clinical stage biopharma developing engineered biologics that selectively target disease specific T cells- tackling autoimmune, inflammatory, and oncological diseases without the side effects of broad immune therapies. Here's why this is on my radar 👇 • New CEO Shao-Lee Lin - founded ACELYRIN, IPO'd at $2B + in under 3 years. Previously AbbVie, Gilead & Amgen •💰Boehringer Ingelheim deal - up to $345M in milestones. $7.5M already collected April 2026 • Collaboration revenue: $5.7M in Q1 2026 vs $0.4M a year ago. That's 14x YoY 📈 • Net loss cut nearly in HALF - $5.2M vs $12.3M YoY • $27.6M private placement closed May 4 - war chest loaded 💵 • Phase 2 data from Ascendant 221 dropping 2H 2026 Key levels to watch: $25 - $40 - $57 Support: $17 New leadership. Growing revenue. Near term catalysts. CommunicatedDisclaimer:stockresearchtoday.com/cue/

$AKTX | Nice move pre-market today

(NASDAQ: $CELZ) Creative Medical Technology Holdings Inc. ✅Float 3.65M ✅Volume gap around 3 ✅My number 1 watch next week ✅20 dollar analyst price target by Roth Capital Partners  Creative Medical Technology Holdings recently achieved its second WHO INN milestone, significantly strengthening its global regulatory position for its cell therapy pipeline. CELZ is a biopharma company focused on developing advanced cell therapies for conditions like chronic pain and diabetes. Communicated Disclaimer / Sponsored Disclosure tinyurl.com/EGDisclaimer $CAR $BYND

(OTC: $BSEM) BioStem Technologies Watching this in 2026 for the $25 target and uplisting potential ✅7 straight profitable quarters ✅$25.50 Zacks target ✅Nasdaq uplisting in focus BSEM kicked off 2026 with a major acquisition valued at up to $40M, adding Neox® and Clarix® while expanding into hospital based wound care. With 88.5% gross margins, $10.5M quarterly revenue, and expected added annual revenue from the deal, this is a profitable small cap worth watching. Communicated Disclaimer tinyurl.com/EquityGenieDis…

(NASDAQ: $ASBP) WATCHING THIS NOW - Float 4.5M - 1 2 3 Candle Stick Pattern - MACD Crossed 2 Hr Chart Beaten down from 1.17 and is now trading around 0.26. ASBP is a biopharma company focused on fast acting sublingual and oral transmucosal products, including drug delivery and supplement offerings. Communicated Disclaimer tinyurl.com/EquityGenieDis… $BYND $OPEN

Avaí Bio, Inc. (OTC: $AVAI) WATCHING THIS INTO NEXT WEEK - Inverted Hammer - Trend Line Hold Targeting Multi-Billion-Dollar Diabetes & Longevity Markets Through Advanced Cell-Based Therapies Developing a bio-artificial pancreas for type 1 and insulin-dependent type 2 diabetes and α-Klotho-based therapies for age-related diseases and anti-aging treatments through proprietary live-cell encapsulation technology. Communicated Disclaimer tinyurl.com/EquityGenieDis… $BYND $OPEN

$CELZ | Fantastic chart here Communicated Disclaimer tinyurl.com/EquityGenieDis…

Avaí Bio, Inc. (OTC: $AVAI) WATCHING THIS INTO NEXT WEEK - Inverted Hammer - Trend Line Hold Targeting Multi-Billion-Dollar Diabetes & Longevity Markets Through Advanced Cell-Based Therapies Developing a bio-artificial pancreas for type 1 and insulin-dependent type 2 diabetes and α-Klotho-based therapies for age-related diseases and anti-aging treatments through proprietary live-cell encapsulation technology. Communicated Disclaimer tinyurl.com/EquityGenieDis… $QNCX $BBGI

My #1 Watch Today! (NASDAQ: $ZENA) Yesterdays post ran 126% here's what im watching today! ✅ Bullish RSI Divergence ✅ Low Float 4M As the Iran war accelerates the shift toward AI-powered drone warfare, ZenaTech (NASDAQ: ZENA) is positioning itself at the intersection of autonomy and national security, building a full ecosystem of drone-versus-drone defense systems, enterprise software, and scalable aerial intelligence networks backed by 20+ acquisitions and growing U.S. defense engagement. Communicated Disclaimer tinyurl.com/2aj4xz7p $OPEN $BYND

(NASDAQ: $PMAX) Watching this one today👀 ✅Hammer on the 4 hour ✅Gap around $0.58 Currently at $0.30 VERY LOW FLOAT AROUND 1M! A Hong Kong Financial Communications Powerhouse Expanding into U.S. Solar, Offering Investors Exposure to Asia's 4.5T Capital Markets and New Energy Growth! Communicated Disclaimer tinyurl.com/EquityGenieDis…

🚨 $RZLV WATCHING THIS FOR THE REST OF THE WEEK! Rezolve Ai just dropped full year 2025 earnings and they beat across the board. The ARR story is no longer a forecast, it's confirmed. 📊 Key numbers: • $46.8M GAAP revenue, ahead of consensus • $232M ARR exit rate, $19.4M December MRR • 66% gross margins, 90%+ on core software • 950+ enterprise customers 📈 2026 outlook: • Revenue guidance raised to $360M • $500M ARR exit target by December • $750M+ funded, zero operational dilution planned The receipts are in. $RZLV heading into 2026 fully loaded. Communicated Disclaimer: tinyurl.com/EquityGenieDis… $UGRO $BYND

🚨 DRONE WARFARE HAS ARRIVED AND $ZENA COULD BE ONE OF THE BIGGEST WINNERS 🚨 The battlefield is changing FAST… and if you’re not watching the drone space, you’re already behind. As global tensions rise, especially with the Iran conflict reshaping modern warfare, one thing is clear: Low-cost drones are dominating high-cost defense systems 🔥 Here’s why this is getting serious attention: ▫️ Drone-vs-Drone Warfare: ZENA is building autonomous interceptor systems designed to STOP hostile drones mid-air ▫️ Game-Changing Cost Advantage: Interceptor P-1 targeting < $5,000 per unit vs. missiles costing 10–100x more ▫️ AI + Autonomous Ecosystem: Not just hardware… full-stack platform (AI, SaaS, analytics, DaaS) ▫️ 20+ Acquisitions fueling rapid expansion and scalability ▫️ Growing U.S. Defense Engagement + global interest (NATO, GCC, allied forces) 💡 THE BIG PICTURE: Modern warfare is shifting toward scalable, AI-driven, low-cost solutions and ZENA is positioning itself right at that intersection. If drones are the future of warfare… then counter-drone systems are the gold rush. ⚡ With a prototype underway and catalysts ahead (development updates, defense contracts, pilots)… this is one to keep firmly on your radar. Communicated - Disclaimer: fh.bio/jcoop

$ZENA On watch with the Iran conflict👀 Outside bar on the daily + Bullish divergence on the RSI! As the Iran conflict accelerates the global drone arms race, $ZENA (ZenaTech) may be quietly positioning itself at the center of autonomous warfare. Through its ZenaDrone subsidiary, ZENA is developing AI-powered drones, autonomous interception systems & maritime defense platforms, at a fraction of missile defense costs. Already generating revenue with triple-digit growth & an expanding Drone-as-a-Service network, unlike many peers still pre-revenue. Worth watching for those seeking early exposure to the drone defense boom. Communicated Disclaimer: tinyurl.com/EquityGenieDis…

NanoViricides ( NYSE: $NNVC ) NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial ✍️Technical Analysis: ✅Buyers present on the trendline ✅Volume gap ahead ✅Over sold RSI It appears that NNVC gave up its gains from the recent news driven run from .96 to 1.27. Now I am watching this due to the fundamental and technical setup. Communicated Disclaimer tinyurl.com/EquityGenieDis… $OPEN $ONDS

Normies have no idea what is coming next… 🛢️📈📈📈📈

$SMCI S.M.C Ya

(OTCQB: $GSTRF | CSE: $GSTR) What a looker! Communicated Disclaimer tinyurl.com/EquityGenieDis… $SLV